10-Q: OptiNose Reports Q1 2024 Results, Revenue Up 25% Despite Prescription Volume Decline

OptiNose, Inc. reported a 25% increase in net product revenue for the first quarter of 2024, driven by higher average revenue per prescription, despite a decrease in overall prescription volume.

Summary

• OptiNose, Inc. reported a net product revenue of $14.88 million for the first quarter of 2024, compared to $11.85 million in the same period of 2023, representing a 25% increase.
• The average net product revenue per prescription increased by 63% to $227 in Q1 2024, up from $139 in Q1 2023, due to changes in the co-pay assistance program.
• Total prescriptions decreased by 23% to 65,500 in Q1 2024, compared to 85,200 in Q1 2023, primarily due to changes in the co-pay program.
• New prescriptions decreased by 19% to 24,700, and refill prescriptions decreased by 26% to 40,800 in Q1 2024 compared to Q1 2023.
• The number of physicians prescribing XHANCE decreased slightly by 1% to 8,451, while the number of physicians with more than 15 prescriptions filled decreased by 26% to 1,023.
• Operating expenses are expected to be between $95 million and $101 million for 2024, with approximately $6 million in stock-based compensation.
• The company expects net product revenues for the full year 2024 to be between $85 million and $95 million, with average net revenue per prescription exceeding $230.
• A registered direct offering completed on May 10, 2024, is expected to generate net proceeds of approximately $55 million.
• The company believes its existing cash and cash equivalents, along with the proceeds from the May 2024 offering, will be sufficient to fund operations and debt service obligations through 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue increased and the company secured additional funding, prescription volumes declined significantly. The company is also facing ongoing losses and debt obligations. The sentiment is neutral, with both positive and negative factors influencing the outlook.

Positives

• The company achieved a significant increase in average net revenue per prescription, indicating improved profitability per unit.
• The recent FDA approval of XHANCE for chronic rhinosinusitis without nasal polyps expands the market opportunity.
• The company has secured additional funding through a registered direct offering, strengthening its financial position.
• The company expects to reduce research and development expenses in 2024 compared to 2023.
• The company is actively seeking a partner to expand the commercialization of XHANCE into primary care.

Negatives

• Total prescriptions for XHANCE decreased by 23% in Q1 2024 compared to Q1 2023.
• New and refill prescriptions both experienced significant declines in Q1 2024.
• The number of physicians with more than 15 XHANCE prescriptions filled decreased by 26% in Q1 2024.
• The company is still experiencing net losses, with a net loss of $14.07 million in Q1 2024.
• The company is subject to minimum purchase commitments with Hikma, which could result in penalties if not met.

Risks

• The company's future success depends on the continued adoption of XHANCE by patients and physicians.
• Payor utilization management criteria could negatively impact XHANCE prescription volumes.
• The company may require additional capital in the future to meet debt obligations and fund operations.
• The company faces competition from other pharmaceutical companies in the market.
• The company is subject to risks related to manufacturing, supply chain, and regulatory compliance.

Future Outlook

The company expects full-year 2024 net product revenues to be between $85 million and $95 million, with average net revenue per prescription exceeding $230. They believe their current cash and the proceeds from the recent offering will fund operations and debt service through 2025.

Management Comments

• The increase in average net product revenues per prescription is primarily the result of changes we made to our co-pay saving program intended to reduce the number of prescriptions filled by patients in commercial insurance plans that either do not cover XHANCE or are in commercial insurance plans that have high deductibles.
• We believe the disruption in services at Change Healthcare, the claims processor for our vendor that administers the XHANCE co-pay support program, hindered access to our co-pay benefit for uncovered patients.
• We believe this disruption had a favorable effect on XHANCE net revenue per prescription and expect it to be isolated to first quarter 2024.

Industry Context

The approval of XHANCE for chronic rhinosinusitis without nasal polyps expands its market potential, as it is the first and only drug therapy approved for this indication. The company is focusing on the ENT and allergy specialist audience while seeking partnerships to extend commercialization into primary care, which is a common strategy for pharmaceutical companies with specialist-focused products.

Comparison to Industry Standards

• The 63% increase in average net revenue per prescription is a significant improvement, suggesting effective pricing strategies or changes in patient access programs. This is a key metric for pharmaceutical companies, as it directly impacts profitability.
• The 23% decrease in total prescriptions is concerning and may indicate challenges in market penetration or patient access. This is a common challenge for new drugs, and the company will need to monitor this trend closely.
• The company's projected operating expenses of $95 million to $101 million for 2024 are typical for a commercial-stage pharmaceutical company with ongoing clinical development and marketing activities. However, the company will need to manage these expenses carefully to achieve profitability.
• The company's reliance on a single product, XHANCE, makes it vulnerable to market changes or competition. Diversification of the product pipeline is a common strategy for pharmaceutical companies to mitigate this risk.
• The company's debt obligations and the need for additional capital are common challenges for biotech companies. The company will need to manage its debt and secure additional funding to support its long-term growth.

Stakeholder Impact

• Shareholders will be impacted by the recent capital raise and the company's financial performance.
• Employees will be affected by the company's ongoing operations and financial stability.
• Customers (patients and physicians) will be impacted by the availability and accessibility of XHANCE.
• Suppliers will be affected by the company's purchasing decisions and payment terms.
• Creditors will be impacted by the company's ability to service its debt obligations.

Next Steps

• The company plans to continue commercialization efforts for XHANCE, focusing on ENT and allergy specialists.
• The company will seek partnerships to expand the commercialization of XHANCE into primary care.
• The company will continue clinical development activities for XHANCE, including studies mandated under the Pediatric Research Equity Act.
• The company will evaluate product candidates and continue to contract to manufacture XHANCE.
• The company will maintain and protect its patent portfolio and service its debt obligations.

Key Dates

Keywords

XHANCE, chronic rhinosinusitis, nasal polyps, prescription, revenue, FDA, co-pay assistance, pharmaceutical, net product revenue, operating expenses